The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank
Open accessAbstract
Objective: Lp(a) (lipoprotein[a]) concentrations are associated with atherosclerotic cardiovascular disease (ASCVD), and new therapies that enable potent and specific reduction are in development. In the largest study conducted to date, we address 3 areas of uncertainty: (1) the magnitude and shape of ASCVD risk conferred across the distribution of lipoprotein(a) concentrations; (2) variation of risk across racial and clinical subgroups; (3) clinical importance of a high lipoprotein(a) threshold to guide therapy. Approach and Results: Relationship of lipoprotein(a) to incident ASCVD was studied in 460 506 middle-aged UK Biobank participants. Over a median follow-up of 11.2 years, incident ASCVD occurred in 22 401 (4.9%) participants. Median lipoprotein(a) concentration was 19.6 nmol/L (25th–75th percentile 7.6–74.8). The relationship between lipoprotein(a) and ASCVD appeared linear across the distribution, with a hazard ratio of 1.11 (95% CI, 1.10–1.12) per 50 nmol/L increment. Substantial differences in concentrations were noted according to race—median values for white, South Asian, black, and Chinese individuals were 19, 31, 75, and 16 nmol/L, respectively. However, risk per 50 nmol/L appeared similar—hazard ratios of 1.11, 1.10, and 1.07 for white, South Asian, and black individuals, respectively. A high lipoprotein(a) concentration defined as ≥150 nmol/L was present in 12.2% of those without and 20.3% of those with preexisting ASCVD and associated with hazard ratios of 1.50 (95% CI, 1.44–1.56) and 1.16 (95% CI, 1.05–1.27), respectively. Conclusions: Lipoprotein(a) concentrations predict incident ASCVD among middle-aged adults within primary and secondary prevention contexts, with a linear risk gradient across the distribution. Concentrations are variable across racial subgroups, but the associated risk appears similar.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consequently, genetic studies found a causal link between elevated Lp(a) levels and a higher risk for CVD diseases,[184–189] and vice versa [190].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [189]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.005 · Cited by 4,945
Goff, D. C., Lloyd-Jones, D. M., Bennett, G., Coady, S., D’Agostino, R. B., Gibbons, R., Greenland, P., Lackland, D. T., Levy, D., O’Donnell, C. J., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437741.48606.98 · Cited by 3,697
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J. J., Gotto, A. M., Kastelein, J. J. P., Köenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · Obstetrical & Gynecological Survey · doi:10.1097/01.ogx.0000344393.60303.0a · Cited by 3,641
Khera, A. V., Chaffin, M., Aragam, K. G., Haas, M. E., Roselli, C., Choi, S. H., Natarajan, P., Lander, E. S., Lubitz, S. A., Ellinor, P. T., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0183-z · Cited by 2,953
Self-citationCollaborators, C. T. T. (. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60367-5 · Cited by 2,833
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
A NEW SERUM TYPE SYSTEM IN MAN—THE Lp SYSTEM
Berg, K. (1963) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1963.tb01808.x · Cited by 1,383
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 573
Dudum, R., Huang, Q., Yan, X., Fonseca, M. A., Jose, P. O., Sarraju, A., Palaniappan, L. P., & Rodríguez, F. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.100940 · Cited by 26
Effects of Inclisiran in Patients With Atherosclerotic Cardiovascular Disease
Wright, R. S., Ray, K. K., Landmesser, U., Koenig, W., Raal, F. J., Leiter, L. A., Conde, L. G., Han, J., & Schwartz, G. G. (2024) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2024.03.025 · Cited by 25
Shah, N. P., Mulder, H. S., Lydon, E. J., Chiswell, K., Hu, X., Lampron, Z. M., Cohen, L., Patel, M. R., Taubes, S., Song, W., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.035610 · Cited by 25
Clarke, R., Wright, N., Lin, K., Yu, C., Walters, R. G., Lv, J., Hill, M., Kartsonaki, C., Millwood, I. Y., Bennett, D., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.072086 · Cited by 28
Stătescu, C., Anghel, L., Benchea, L.-C., Tudurachi, B.-S., Leonte, A., Zăvoi, A., Zota, I. M., Prisacariu, C., Radu, R., Șerban, I.-L., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065927 · Cited by 25
Li, S., Xu, Z., Wang, Y., Chen, L., Wang, X., Zhou, Y., Lei, D., Zang, G., & Wang, G. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.06.016 · Cited by 25
Lipoprotein(a): An important piece of the ASCVD risk factor puzzle across diverse populations
Ciffone, N. A., McNeal, C. J., McGowan, M. P., & Ferdinand, K. C. (2023) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2023.100350 · Cited by 25
Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemia
Tromp, T. R., Ibrahim, S., Nurmohamed, N. S., Peter, J., Zuurbier, L. C., Defesche, J. C., Reeskamp, L. F., Hovingh, G. K., & Stroes, E. S. G. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.11.020 · Cited by 24
Toward Understanding Cardiovascular Risk Burden in South Asians
Gupta, K., Modi, S., & Ananthasubramaniam, K. (2022) · JACC Asia · doi:10.1016/j.jacasi.2022.10.005 · Cited by 24
Matveyenko, A., Matienzo, N., Ginsberg, H. N., Nandakumar, R., Seid, H., Ramakrishnan, R., Holleran, S., Thomas, T. A., & Reyes‐Soffer, G. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100336 · Cited by 24
Pelacarsen: Mechanism of action and Lp(a)-lowering effect
Bhatia, H. S., Bajaj, A., Goonewardena, S. N., & Moriarty, P. M. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.06.004 · Cited by 25
Lipoprotein(a): a genetically determined risk factor for Cardiovascular disease
Marcovina, S. M. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2229915 · Cited by 25
Ballantyne, C. M., & Norata, G. D. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf606 · Cited by 23
Lipoprotein(a) distribution and its association with carotid arteriopathy in the Chinese population
Lin, L., Deng, K., Chen, Z., Lei, F., Qin, J., Huang, X., Sun, T., Zhang, X., Hu, Y., Zhang, P., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.03.007 · Cited by 22
Heterogeneity of Lipoprotein(a) Levels Among Hispanic or Latino Individuals Residing in the US.
Joshi, P., Marcovina, S., Orroth, K., López, J. A., Kent, S. T., Kaplan, R., Swett, K., Sotres-Alvarez, D., Thyagarajan, B., Slipczuk, L., et al. (2023) · JAMA cardiology · doi:10.1001/jamacardio.2023.1134 · Cited by 19
Assini, J. M., Clark, J. R., Youssef, A., Xing, C., Doerfler, A. M., Park, S. H., Saxena, L., Yaseen, A. B., Borén, J., Gros, R., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.05.019 · Cited by 22
Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor
Koschinsky, M. L., Stroes, E. S. G., & Kronenberg, F. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106843 · Cited by 22
Rethinking cardiovascular risk: The emerging role of lipoprotein(a) screening
Clair, V., Zirille, F. M., & Gill, E. A. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.100945 · Cited by 21
Wang, C., Fu, H., Xu, H., Yang, H., Min, X., Wu, W., Liu, Z., Li, D., Dong, Y., & Chen, J. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1576602 · Cited by 21
The Inherited Hypercholesterolemias
Loh, W. J., & Watts, G. F. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2022.02.006 · Cited by 21
The ins and outs of lipoprotein(a) assay methods
Heydari, M., Rezayi, M., Ruscica, M., Jamialahmadi, T., Johnston, T. P., & Sahebkar, A. (2024) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/176653 · Cited by 21
Within-person stability of lipoprotein(a) concentration
Ghouse, J., Ahlberg, G., Rand, S. A., OLESEN, M. S., Vilhjálmsson, B. J., Stender, S., & Bundgaard, H. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae652 · Cited by 21
The year in cardiovascular medicine 2021: dyslipidaemia
Tokgözoğlu, L. S., Orringer, C. E., Ginsberg, H. N., & Catapano, A. L. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab875 · Cited by 22
Lipoprotein(a) – From Biomarker to Therapy: A Review for the Clinician
Jha, M., Raber, I., & Gelfand, E. V. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.02.034 · Cited by 20
Kaur, G., Berman, A. N., Biery, D. W., Besser, S. A., Wu, W. Y., Weber, B., Honigberg, M. C., Nasir, K., Gulati, M., Carli, M. F. D., et al. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.035353 · Cited by 20
Role of neutrophils on cancer cells and other immune cells in the tumor microenvironment
Zhong, J., Zong, S., Wang, J., Feng, M., Wang, J., Zhang, H., & Xiong, L. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119493 · Cited by 20
Januzzi, J. L., van Kimmenade, R. R. J., Liu, Y., Hu, X., Browne, A., Plutzky, J., Tsimikas, S., Blankstein, R., & Natarajan, P. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.034774 · Cited by 20
Lipoprotein (a): Underrecognized Risk with a Promising Future
Manzato, M., Wright, R. S., Jaffe, A. S., & Vasile, V. C. (2024) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2511393 · Cited by 19
Triglyceride Metabolism Modifies Lipoprotein(a) Plasma Concentration
Ramos-Cáceres, M., Lamíquiz-Moneo, I., Cenarro, A., Calmarza, P., Marco-Benedí, V., Bea, A. M., Mateo‐Gállego, R., Puzo, J., Ordovás, J. M., Civeira, F., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac412 · Cited by 19
New Horizons: Revival of Lipoprotein (a) as a Risk Factor for Cardiovascular Disease
Nestel, P. J., Loh, W. J., Ward, N. C., & Watts, G. F. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac541 · Cited by 19
Koskinas, K. C., Häner, J. D., Ueki, Y., Otsuka, T., Lønborg, J., Shibutani, H., Kakizaki, R., Kaiser, C. A., van Geuns, R., Ondracek, A. S., et al. (2024) · Circulation Cardiovascular Imaging · doi:10.1161/circimaging.124.016683 · Cited by 19
Li, Q., Chen, Y., Yu, L., Zhu, L., Wang, Z., Jiao, S., Wu, C., Tu, Y., Wu, Y., Guo, Z., et al. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.04.007 · Cited by 19
Bigazzi, F., Minichilli, F., Sbrana, F., Pino, B. D., Corsini, A., Watts, G. F., Sirtori, C. R., Ruscica, M., & Sampietro, T. (2020) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2020.158869 · Cited by 18
Hu, X., Cristino, J. R., Gautam, R., Mehta, R. K., Amari, D. T., Heo, J. H., Wang, S., & Wong, N. D. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100476 · Cited by 18
Bellomo, T. R., Bramel, E. E., Lee, J., Urbut, S., Flores, A. M., Yu, Z., Koyama, S., Truong, B. M. T., Haidermota, S., Eagleton, M. J., et al. (2025) · Circulation · doi:10.1161/circulationaha.124.073579 · Cited by 17
Self-citationZhou, Z., Parra-Soto, S. L., Boonpor, J., Petermann-Rocha, F. E., Welsh, P. I., Mark, P. B., Sattar, N. A., Pell, J. P., Celis-Morales, C. A., & Ho, F. K. W. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101715 · Cited by 17
Genovesi, S., Giussani, M., Lieti, G., Orlando, A., Patti, I., & Parati, G. (2023) · Biomedicines · doi:10.3390/biomedicines11061661 · Cited by 17
Panagiotakos, D. B., Chrysohoou, C. A., Pitsavos, C., & Tsioufis, K. P. (2023) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2023.10.001 · Cited by 17
Eidensohn, Y., Bhatla, A., Ding, J., Blumenthal, R. S., Martin, S. S., & Marvel, F. A. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100686 · Cited by 18
Lipoprotein(a), Residual Cardiovascular Risk, and the Search for Targeted Therapy
Blaha, M. J., & Bhatia, H. S. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.03.370 · Cited by 17
Lipid profile and lipoprotein(a) testing
Parhofer, K. G., & Laufs, U. (2023) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.m2023.0150 · Cited by 16
Lipoprotein(a) in clinical practice: A guide for the clinician
Krittanawong, C., Maitra, N. S., Sherbini, A. E., Shah, N. R., Lavie, C. J., Shapiro, M. D., & Virani, S. S. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.07.006 · Cited by 17
Zisman, E., Hossain, M. B., Funderburg, N., Christenson, R. H., Jeudy, J. J., Burrowes, S. A. B., Hays, A. G., George, N., Freeman, M. L., Rebuck, H., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.02.003 · Cited by 16
Dyrbuś, K., Mędrala, Z., Konsek, K., Nowowiejska‐Wiewióra, A., Trzeciak, P., Skrzypek, M., Cieśla, D., Banach, M., & Gąsior, M. (2024) · Archives of Medical Science · doi:10.5114/aoms/188294 · Cited by 18
Development and multinational validation of an algorithmic strategy for high Lp(a) screening
Aminorroaya, A., Dhingra, L. S., Oikonomou, E. K., Saadatagah, S., Thangaraj, P., Shankar, S. V., Spatz, E. S., & Khera, R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00469-1 · Cited by 16
Kaur, G., Rosenson, R. S., Gencer, B., López, J. A. G., Lepor, N. E., Baum, S. J., Stout, E., Gaudet, D., Knüsel, B., Park, J., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae781 · Cited by 16
FAN, W., Wu, C., & Wong, N. D. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.124.004631 · Cited by 16
Mora, S., & Kronenberg, F. (2025) · JAMA · doi:10.1001/jama.2025.2373 · Cited by 16
Mohammadnia, N., van Broekhoven, A., Bax, W. A., Eikelboom, J. W., Mosterd, A., Fiolet, A. T. L., Tijssen, J. G. P., Thompson, P. L., de Kleijn, D. P. V., Tsimikas, S., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119211 · Cited by 16
Razavi, A. C., Bhatia, H. S., Blumenthal, R. S., Shapiro, M. D., & Mehta, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16469 · Cited by 16
Measuring lipoprotein(a): do it without ifs and buts
Kronenberg, F. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab180 · Cited by 16
Sukkari, M. H., Al-bast, B., Tamimi, R. A., Giesing, W., & Siddique, M. S. (2023) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2023.100579 · Cited by 15
Mukherjee, D., & Nissen, S. E. (2023) · Current Vascular Pharmacology · doi:10.2174/0115701611267835231210054909 · Cited by 15
Wang, G., Xia, M., Liang, C., Pu, F., Liu, S., & Jia, D. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1362893 · Cited by 15
Lipoprotein(a) as a Stroke Biomarker: Pathophysiological Pathways and Therapeutic Implications
Panagiotopoulos, E., Palaiodimou, L., Theodorou, A., Papagiannopoulou, G., Bakola, E., Chondrogianni, M. E., Psychogios, K., Kargiotis, O., Safouris, A., Vlachopoulos, C. V., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14092990 · Cited by 15
Parthymos, I., Kostapanos, M. S., Mikhailidis, D. P., & Florentin, M. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab052 · Cited by 15
Lipoprotein(a): Role in atherosclerosis and new treatment options
Tomić-Naglić, D., Manojlovic, M. S., Pejaković, S., Stepanović, K., & Prodanović, J. (2023) · Biomolecules and Biomedicine · doi:10.17305/bb.2023.8992 · Cited by 15
Zierfuss, B., Höbaus, C., Feldscher, A., Hannes, A., Mrak, D., Koppensteiner, R., Stangl, H., & Schernthaner, G.-H. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.10.002 · Cited by 14
Lipoprotein (a) and myocardial infarction: impact on long-term mortality
Zhang, J., Jia, L., Yang, Y., Xiao, A. Y., & Lin, X. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01841-z · Cited by 14
Dong, W., Zhong, X., Yuan, K., Miao, M.-Y., Zhai, Y., Che, B., Xu, T., Xu, X. M., & Zhong, C. (2023) · Postgraduate Medical Journal · doi:10.1093/postmj/qgad070 · Cited by 14
Shapiro, M. D., Haddad, T. M., WEINTRAUB, H. S., Baum, S. J., Abdul-Nour, K., Sarwat, S., Paluy, V., Boatwright, W., Browne, A., Ayaz, I., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.11.007 · Cited by 14
LP(a): The new marker of high cardiovascular risk
Averna, M. R., & Cefalu, A. B. (2024) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2024.103845 · Cited by 14
Marchis, G. M. D., Dittrich, T. D., Malik, R., Zietz, A. V., Kriemler, L. F., Ference, B. A., Dichgans, M., & Georgakis, M. K. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.09.007 · Cited by 14
Demographics of lipoprotein(a) and stroke: The UK biobank
Kao, A. S., Kermanshahchi, J., Khosrowjerdi, S., Razavi, A. C., Levene, J., Reyes, M., Garg, P. K., Longstreth, W. T., Rannikmäe, K., Sudlow, C. L. M., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101055 · Cited by 13
Lipoprotein (a): A new target for pharmacological research and an option for treatment
Pirillo, A., & Catapano, A. L. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.07.021 · Cited by 14
Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men
Ezzat, D., Lopez, D. M., Claggett, B. L., Li, L., Mohammadnia, N., Schuermans, A., Hemeryck, J., Chang, A., Murillo, S., O’Donoghue, M. L., et al. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag252 · Cited by 13
Self-citationInter-Individual Variability in Lipid Response: A Narrative Review
Patnaik, S., Pollevick, M. E., Lara-Breitinger, K. M., & Stone, N. J. (2022) · The American Journal of Medicine · doi:10.1016/j.amjmed.2022.06.018 · Cited by 13
França, V., Gomes, É. I. L., de Campos, E. V. S., Zago, V. H. D. S., Nunes, V. S., & de Faria, E. C. (2022) · Clinics · doi:10.1016/j.clinsp.2022.100107 · Cited by 13
Lipoprotein(a): cardiovascular risk and emerging therapies
Fujino, M., & Nicholls, S. J. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2197593 · Cited by 14
Farina, J., Pereyra, M., Mahmoud, A., Chao, C., Barry, T., Demeter, S. H., Ayoub, C., & Arsanjani, R. (2023) · Pharmaceuticals · doi:10.3390/ph16070919 · Cited by 13
Fichtner, I., Macchi, C., Rizzuto, A. S., Carugo, S., Corsini, A., & Ruscica, M. (2024) · Atherosclerosis Plus · doi:10.1016/j.athplu.2024.09.004 · Cited by 13
Garcia, D. A., Pierre, A. F., Quirino, L., Acharya, G., Vasudevan, A., Pei, Y., Chung, E., Chang, J. Y. H., Lee, S., Endow, M., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.11.020 · Cited by 13
Fathieh, S., Tang, O., Gray, M. P., Zanchin, C., Vernon, S. T., Genetzakis, E., Tran, C., SULLIVAN, D. R., Nicholls, S. J., Celermajer, D. S., et al. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf323 · Cited by 13
Lipoprotein(a) in Cardiovascular Diseases: Insight From a Bibliometric Study
Šuran, D., Vošner, H. B., Završnik, J., Kokol, P., Sinkovič, A., Kanič, V., Kokol, M., Naji, F. H., & Završnik, T. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.923797 · Cited by 14
Colantonio, L. D., Goonewardena, S. N., Wang, Z., Jackson, E. A., Farkouh, M. E., Li, M., Malick, W. A., Kent, S. T., López, J. A. G., Muntner, P., et al. (2023) · Journal of clinical lipidology · doi:10.1016/j.jacl.2023.06.001 · Cited by 13
Orfanos, P., Fonseca, A. F., Hu, X., Gautam, R., Montgomery, G., Studer, R. L., Kaur, J., Saxena, N., & Kaushik, N. (2023) · PLoS ONE · doi:10.1371/journal.pone.0294250 · Cited by 12
Amstler, S., Streiter, G., Pfurtscheller, C., Forer, L., Maio, S. D., Weißensteiner, H., Paulweber, B., Schönherr, S., Kronenberg, F., & Coassin, S. (2024) · Genome Medicine · doi:10.1186/s13073-024-01391-8 · Cited by 12
Manzato, M., Meeusen, J. W., Donato, L. J., Jaffe, A. S., & Vasile, V. C. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100886 · Cited by 11
Hoogeveen, R. C., Diffenderfer, M. R., Lim, E., Liu, C., Ikezaki, H., Guan, W., Tsai, M. Y., & Ballantyne, C. M. (2025) · Nutrients · doi:10.3390/nu17081324 · Cited by 12
Elevated Lp(a) and course of COVID-19: Is there a relationship?
Pawlos, A., Gorzelak‐Pabiś, P., Staciwa, M., & Broncel, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0266814 · Cited by 12
Lipoprotein(a): Insights for the Practicing Clinician
Telyuk, P., Austin, D., Luvai, A., & Zaman, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11133673 · Cited by 12
Loh, W. J., & Watts, G. F. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000789 · Cited by 12
Lp(a) - an overlooked risk factor
Laffin, L. J., & Nissen, S. E. (2023) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2023.01.003 · Cited by 12
Impact of High Lipoprotein(a) on Long‐Term Survival Following Coronary Artery Bypass Grafting
Yuan, S., Li, F., Zhang, H., Zeng, J., Su, X., Qu, J., Lin, S., Gu, D., Rao, C., Zhao, Y., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031322 · Cited by 13
Lipoprotein(a)-lowering therapies: a promising future
Zhang, J., Návar, A. M., & Tokgözoğlu, L. S. (2026) · European Heart Journal · doi:10.1093/eurheartj/ehag092 · Cited by 13
Rahimi, M., Khanahmad, H., Gharipour, M., Roohafza, H., Dianatkhah, M., Khosravi, E., Sadeghian, L., & Sadeghi, M. (2021) · PubMed Central · doi:10.22122/arya.v17i0.2369 · Cited by 11
Thomas, P. E., Vedel‐Krogh, S., & Kamstrup, P. R. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001168 · Cited by 11
Kalwick, M., & Roth, M. M. (2025) · Nutrients · doi:10.3390/nu17040659 · Cited by 13
Lyle, A. N., Flores, E. N., Coffman, C. C., Doty, A., Sugahara, O., Kronenberg, F., Ruhaak, L. R., Cobbaert, C. M., & Vesper, H. W. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.02.010 · Cited by 11
Anchouche, K., Baass, A. W., & Thanassoulis, G. (2025) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2025.110929 · Cited by 11
Wodaje, T., Littmann, K., Häbel, H., Bottai, M., Bäck, M., Parini, P., & Brinck, J. W. (2022) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2022.02.016 · Cited by 11
Approach to risk stratification of atherosclerotic cardiovascular disease
Esau, D., & Abramson, B. L. (2022) · Canadian Family Physician · doi:10.46747/cfp.6809654 · Cited by 11
Marlęga-Linert, J., Gąsecka, A., van der Pol, E., Kuchta, A., Filipiak, K. J., Fijałkowski, M., Gruchała, M., Nieuwland, R., & Mickiewicz, A. (2024) · Scientific Reports · doi:10.1038/s41598-024-51782-5 · Cited by 11
Effectiveness of cascade screening for elevated lipoprotein(a), an underdiagnosed family disorder
Annink, M. E., Janssen, E. S., & Reeskamp, L. F. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000951 · Cited by 10
Yurtseven, E., Ural, D., Gürsoy, E., Cunedioglu, B. O., Guler, O. U., Baysal, K., Aytekin, S., Aytekin, V., & Kayıkçıoğlu, M. (2024) · Clinical Cardiology · doi:10.1002/clc.70012 · Cited by 10
Aminorroaya, A., Dhingra, L. S., Oikonomou, E. K., & Khera, R. (2025) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.124.004632 · Cited by 10
Residual lipoprotein(a)-associated risk in patients with stroke or transient ischemic attack
Hoshino, T., Mizuno, T., Arai, S., Hosoya, M., Wako, S., Takahashi, S., Oshima, R., Higuchi, E., Ishizuka, K., Toi, S., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.119231 · Cited by 10
Impact of PCSK9 inhibitors on lipoprotein(a) levels: a multi-centre study
Bhatia, H. S., Cuomo, R. E., Ramsis, M., Mahmud, E., Taub, P. R., & Wilkinson, M. J. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf734 · Cited by 10
Emerging therapies targeting lipoprotein(a): the next frontier in cardiovascular risk reduction
Alhomoud, I. S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1727918 · Cited by 10
Nordestgaard, A. G., Chasman, D. I., Moorthy, M. V., Kraaijenhof, J. M., Cook, N. R., Lee, I.-M. M., Buring, J. E., & Ridker, P. M. (2026) · JAMA Cardiology · doi:10.1001/jamacardio.2025.5043 · Cited by 10
Metadata
- Authors
- Patel, A. P., Wang, M., Pirruccello, J. P., Ellinor, P. T., Ng, K., Kathiresan, S., & Khera, A. V.
- Affiliations
- Broad Institute (US)
- IBM Research - Cambridge (United States) (US)
- Corresponding author
- Khera, Amit V.
- ORCID
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2021-01
- Volume
- 41
- Issue
- 1
- Pages
- 465-474
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- PMC
- PMC7769893
- OpenAlex
- W3097307979
- Cited by
- 567
- References
- 50
- Citations by year
- 2026: 135 · 2025: 147 · 2024: 110 · 2023: 89 · 2022: 60 · 2021: 25
- FWCI
- 39.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- Arteriosclerosis Thrombosis and Vascular Biology (publishedVersion, other-oa)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Heart Association (R01 HL128914, 18SFRN34110082)
- Massachusetts General Hospital
- Broad Institute
- Fondation Leducq (K24HL105780, 18SFRN34110082, 1RO1HL092577, T32HL007208, 14CVD01, R01HL128914)
- Medical Research Council (MC_PC_17228)
- National Heart, Lung, and Blood Institute (1RO1HL092577, R01HL128914, K24HL105780, R01HL092577, T32HL007208)
- National Human Genome Research Institute (K08HG010155, 18SFRN34110082)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- lipoprotein(a), atherosclerotic cardiovascular disease, incident cardiovascular events, racial differences, risk gradient, primary prevention, secondary prevention, middle-aged adults, UK Biobank
- MeSH terms
- Race Factors, Heart Disease Risk Factors, Adult, Aged, Female, United Kingdom, Humans, Male, Middle Aged, Primary Prevention, Prognosis, Time Factors, Biomarkers, Incidence, Lipoprotein(a), Biological Specimen Banks, Risk Assessment, Atherosclerosis, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
